ILMOFOSINE (BM-41.440) IN RENAL-CELL CANCER - A MULTICENTER PHASE-II STUDY

Authors
HERRMANN R MANEGOLD C BREMER K BECHER R KRIEGBAUM H EDLER L QUEISSER W
Citation
R. Herrmann et al., ILMOFOSINE (BM-41.440) IN RENAL-CELL CANCER - A MULTICENTER PHASE-II STUDY, Onkologie, 17(3), 1994, pp. 278-279
Citations number
4
Categorie Soggetti
Oncology
Journal title
Onkologie → ACNP
ISSN journal
0378584X
Volume
17
Issue
3
Year of publication
1994
Pages
278 - 279
Database
ISI
SICI code
0378-584X(1994)17:3<278:I(IRC->2.0.ZU;2-0
Abstract
Background: Ilmofosine is an ether lipid with antineoplastic activity in experimental systems. Since there is no established systemic treatm ent for metastatic renal cell cancer, a trial with this new agent seem ed to be warranted. Patients and Methods: Patients with measurable met astatic renal cell cancer without prior systemic treatment received il mofosine between 150 and 300 mg per day orally until disease progressi on. Results: There have been no objective responses among the 19 evalu able patients. Dose-limiting toxicity was gastrointestinal intolerance . Conclusions: Oral ilmofosine is ineffective in metastatic renal cell cancer.